Editorials

Long term adjuvant therapy for primary breast cancer

A major clinical trial of long term adjuvant treatment with tamoxifen in women with primary breast cancer has been stopped by the National Cancer Institute of America on the grounds that treatment for more than five years is unlikely to be beneficial.¹ The institute's report relates to trials carried out by the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh. Between 1981 and 1993 over 4000 women who had undergone surgery with or without radiotherapy for oestrogen receptor positive breast cancer but who had no lymph node involvement were recruited into two randomised clinical trials.

The first of these examined the effect on survival of adjuvant therapy with tamoxifen. Ten years after primary treatment, patients receiving the drug had an overall survival of 78% compared with 75% in the placebo group, results which are in line with those in . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Adjuvant treatment with tamoxifen

Michael Baum and Jack Cuzick
BMJ 1996 312: 1036. [Extract] [Full Text]

Local research ethics committees should review their approval of prevention trial

Catherine Read
BMJ 1996 312: 1036. [Extract] [Full Text]

Recruitment into studies assessing optimum duration of treatment must continue

Helena Earl, Pat Baker, David Kerr, Martin Lee, Richard Gray, and Michael Baum
BMJ 1996 312: 1036-1037. [Extract] [Full Text]

Multicentre trial should be welcomed

A P Corder
BMJ 1996 312: 1037. [Extract] [Full Text]

Clinicians must share knowledge with their patients more readily

Heather Goodare
BMJ 1996 312: 1037. [Extract] [Full Text]

This article has been cited by other articles:

• Swerdlow, A. J., Jones, M. E., For the British Tamoxifen Second Cancer Study Grou, (2005). Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study. JNCI J Natl Cancer Inst 97: 375-384 [Abstract] [Full text]  
• Fisher, B., Dignam, J., Bryant, J., Wolmark, N. (2001). Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. JNCI J Natl Cancer Inst 93: 684-690 [Abstract] [Full text]  
• Eagle, M. C (1996). Manufacturer's reply. BMJ 313: 945-945 [Full text]  
• Bulbrook, R D (1996). Adjuvant treatment with tamoxifen. BMJ 313: 493c-494 [Full text]  
• Baum, M., Cuzick, J. (1996). Adjuvant treatment with tamoxifen. BMJ 312: 1036-1036 [Full text]  
• Corder, A P (1996). Multicentre trial should be welcomed. BMJ 312: 1037-1037 [Full text]  
• Read, C. (1996). Local research ethics committees should review their approval of prevention trial. BMJ 312: 1036a-1036 [Full text]  
• Earl, H., Baker, P., Kerr, D., Lee, M., Gray, R., Baum, M. (1996). Recruitment into studies assessing optimum duration of treatment must continue. BMJ 312: 1036b-1037 [Full text]  
• Goodare, H. (1996). Clinicians must share knowledge with their patients more readily. BMJ 312: 1037a-1037 [Full text]  
• Fitzpatrick, M. (1996). Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. BMJ 312: 1037b-1037 [Full text]